U.S. Markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.05
    +0.41 (+0.90%)
     
  • Gold

    1,840.70
    -0.40 (-0.02%)
     
  • Silver

    24.29
    +0.15 (+0.63%)
     
  • EUR/USD

    1.2124
    -0.0025 (-0.21%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • GBP/USD

    1.3431
    -0.0022 (-0.16%)
     
  • USD/JPY

    104.1500
    +0.2900 (+0.28%)
     
  • BTC-USD

    18,942.72
    -15.29 (-0.08%)
     
  • CMC Crypto 200

    371.16
    -8.09 (-2.13%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Pipeline Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

·1 min read

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will participate in a fireside chat and investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference, a fully virtual management access conference, taking place December 1-3.

Today, the company also participated in the Guggenheim Healthcare Talks event. Carmine Stengone took part in the Neurology-Focused Private Company Panel on Epilepsy and Neuro-regeneration.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005931/en/

Contacts

Company Contact:
Carmine Stengone
President and CEO
info@pipelinetherapeutics.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@gilmartinir.com